InflaRx
Clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, particularly C5a inhibitors for severe inflammatory conditions. Publicly traded on NASDAQ (IFRX).
Notes
InflaRx is a clinical-stage biopharmaceutical company focused on developing anti-inflammatory therapeutics that target the complement system, a key component of the innate immune system. The company's lead candidate vilobelimab is a monoclonal antibody that inhibits C5a, a potent inflammatory mediator.
Founded in Germany in 2007, InflaRx went public on NASDAQ (ticker: IFRX) in 2017. The company has developed vilobelimab for severe inflammatory conditions including hidradenitis suppurativa, pyoderma gangrenosum, and most notably for COVID-19-related acute respiratory distress syndrome (ARDS).
Vilobelimab received emergency use authorization (EUA) in the US for COVID-19 treatment in 2023, representing a significant milestone for the complement inhibition approach.
Team
- Niels Riedemann, M.D., Ph.D. - CEO & Co-founder
- LinkedIn: linkedin.com/in/nielsriedemann
- Experienced team in immunology and drug development
Additional Research Findings
- Founded in 2007, headquartered in Jena, Germany
- Public company on NASDAQ (ticker: IFRX) since 2017
- Lead candidate: vilobelimab (anti-C5a antibody)
- EUA for COVID-19 ARDS treatment (2023)
- Clinical trials in hidradenitis suppurativa, pyoderma gangrenosum
- Complement system therapeutics
- Bain Capital Life Sciences investor
- German biotech with US listing
- Pioneer in C5a inhibition approach